173 related articles for article (PubMed ID: 28831147)
1. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
[TBL] [Abstract][Full Text] [Related]
2. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Wu SC; Li LS; Kopp N; Montero J; Chapuy B; Yoda A; Christie AL; Liu H; Christodoulou A; van Bodegom D; van der Zwet J; Layer JV; Tivey T; Lane AA; Ryan JA; Ng SY; DeAngelo DJ; Stone RM; Steensma D; Wadleigh M; Harris M; Mandon E; Ebel N; Andraos R; Romanet V; Dölemeyer A; Sterker D; Zender M; Rodig SJ; Murakami M; Hofmann F; Kuo F; Eck MJ; Silverman LB; Sallan SE; Letai A; Baffert F; Vangrevelinghe E; Radimerski T; Gaul C; Weinstock DM
Cancer Cell; 2015 Jul; 28(1):29-41. PubMed ID: 26175414
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
Silvennoinen O; Hubbard SR
Cancer Cell; 2015 Jul; 28(1):1-2. PubMed ID: 26175407
[TBL] [Abstract][Full Text] [Related]
4. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood ML; Liu Y; Harkins SK; Weinstock DM; Yang L; Stevenson KE; Plana OD; Dong J; Cirka H; Jones KL; Virtanen AT; Gupta DG; Ceas A; Lawney B; Yoda A; Leahy C; Hao M; He Z; Choi HG; Wang Y; Silvennoinen O; Hubbard SR; Zhang T; Gray NS; Li LS
Cell Chem Biol; 2023 Jun; 30(6):618-631.e12. PubMed ID: 37290440
[TBL] [Abstract][Full Text] [Related]
5. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Codilupi T; Szybinski J; Arunasalam S; Jungius S; Dunbar AC; Stivala S; Brkic S; Albrecht C; Vokalova L; Yang JL; Buczak K; Ghosh N; Passweg JR; Rovo A; Angelillo-Scherrer A; Pankov D; Dirnhofer S; Levine RL; Koche R; Meyer SC
Clin Cancer Res; 2024 Feb; 30(3):586-599. PubMed ID: 37992313
[TBL] [Abstract][Full Text] [Related]
6. Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity.
Zhao C; Khadka DB; Cho WJ
Curr Med Chem; 2016; 23(13):1331-55. PubMed ID: 27048338
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
9. Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.
Chen Y; Yu W; Jiang CC; Zheng JG
Molecules; 2018 Jun; 23(6):. PubMed ID: 29925769
[TBL] [Abstract][Full Text] [Related]
10. Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.
Mielecki M; Milner-Krawczyk M; Grzelak K; Mielecki D; Krzysko KA; Lesyng B; Priebe W
Curr Cancer Drug Targets; 2014; 14(7):638-51. PubMed ID: 25146330
[TBL] [Abstract][Full Text] [Related]
11. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
Sadras T; Heatley SL; Kok CH; McClure BJ; Yeung D; Hughes TP; Sutton R; Ziegler DS; White DL
Cancer Genet; 2017 Oct; 216-217():86-90. PubMed ID: 29025600
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
Nair PC; Piehler J; Tvorogov D; Ross DM; Lopez AF; Gotlib J; Thomas D
Blood Cancer Discov; 2023 Sep; 4(5):352-364. PubMed ID: 37498362
[TBL] [Abstract][Full Text] [Related]
13. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
[TBL] [Abstract][Full Text] [Related]
14. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
Kesarwani M; Huber E; Kincaid Z; Evelyn CR; Biesiada J; Rance M; Thapa MB; Shah NP; Meller J; Zheng Y; Azam M
Sci Rep; 2015 Sep; 5():14538. PubMed ID: 26419724
[TBL] [Abstract][Full Text] [Related]
15. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
17. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.
Kong X; Sun H; Pan P; Zhu F; Chang S; Xu L; Li Y; Hou T
Phys Chem Chem Phys; 2018 Feb; 20(7):4851-4863. PubMed ID: 29383359
[TBL] [Abstract][Full Text] [Related]
18. Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.
Wu QY; Ma MM; Tong YX; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2018 Oct; 117():271-279. PubMed ID: 29842959
[TBL] [Abstract][Full Text] [Related]
19. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
Ni Z; Wang X; Zhang T; Jin RZ
Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]